Natixis’s Myriad Genetics MYGN Stock Holding History

Natixis’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,041	Closed	-$44.1K	–	1124
2022 Q4	$44.1K	Buy	+3,041	New	+$56.7K	﹤0.01%	929
2022 Q1	–	Sell	-13,450	Closed	-$371K	–	1268
2021 Q4	$371K	Sell	13,450 -15,933	-54%	-$462K	﹤0.01%	1090
2021 Q3	$949K	Buy	29,383 +22,383	+320%	+$743K	﹤0.01%	902
2021 Q2	$214K	Hold	7,000	–	–	﹤0.01%	813
2021 Q1	$213K	Buy	+7,000	New	+$199K	﹤0.01%	1022
2018 Q4	–	Sell	-10,230	Closed	-$471K	–	781
2018 Q3	$471K	Buy	10,230 +4,123	+68%	+$183K	﹤0.01%	636
2018 Q2	$228K	Buy	+6,107	New	+$206K	﹤0.01%	802
2014 Q1	–	Sell	-105,321	Closed	-$2.21M	–	572
2013 Q4	$2.21M	Buy	105,321 +66,144	+169%	+$1.67M	0.02%	284
2013 Q3	$921K	Buy	39,177 +14,655	+60%	+$416K	0.01%	328
2013 Q2	$659K	Buy	+24,522	New	+$711K	0.01%	313

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Natixis's MYGN Position: Q1 2023 in Review

Natixis sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 3,041 shares — an estimated $44.1K sold.

Natixis first reported a position in MYGN in Q2 2013 and held it in 10 quarters. The position peaked at $2.21M in Q4 2013. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Natixis reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Natixis sold 3,041 Myriad Genetics shares in Q1 2023, an estimated $44.1K.
Natixis first reported a position in Myriad Genetics in Q2 2013 and held it in 10 quarters.
Natixis's Myriad Genetics position peaked at $2.21M in Q4 2013.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Natixis's 13F filing for Q1 2023, filed 12 May 2023.